Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 25Breast Neoplasms 14Neoplasms 12Myelodysplastic Syndromes 12Prostatic Neoplasms 10Multiple Myeloma 8Lung Neoplasms 7Stomach Neoplasms 6Sarcoma 6Ovarian Neoplasms 5Leukemia, Myelomonocytic, Chronic 5Recurrence 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumor 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Solid Tumor 3Small Cell Lung Carcinoma 3Pain 3Mucositis 3Lymphoma, T-Cell, Peripheral 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma, Hepatocellular 3Stomatitis 2Skin Neoplasms 2

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × Injections × Clear all
NCT06173037 2026-01-07

RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

RemeGen Co., Ltd.

Phase 2 Completed
43 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡